Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Andersen

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Cancer Research|August 17, 2001
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patientsM H Andersen, L O Pedersen, B Capeller, et al.
The British Journal of Dermatology|January 1, 2019
Health literacy: a new piece of the puzzle in psoriasis care? A cross-sectional studyM H Larsen, Y A S Strumse, C R Borge, et al.
Cancer Research|February 24, 2001
Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patientsD Schrama, M H Andersen, P Terheyden, et al.
Scandinavian Journal of Immunology|November 25, 2003
Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progressionP Terheyden, D Schrama, L Ø Pedersen, et al.
Journal of Dairy Science|January 30, 2002
Purification of MUC1 from bovine milk-fat globules and characterization of a corresponding full-length cDNA cloneL T Pallesen, M H Andersen, R L Nielsen, et al.
Scandinavian Journal of Immunology|May 22, 2014
Induction of Bcl-xL-specific cytotoxic T lymphocytes in miceH L Larsen, M H Andersen, H H Wandall, et al.
Leukemia|July 2, 2013
Functional characterization of Foxp3-specific spontaneous immune responsesS K Larsen, S Munir, A Woetmann, et al.
Leukemia|April 11, 2008
Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a 'good' mHag?T Kollgaard, S Reker Hadrup, S L Petersen, et al.
European Journal of Immunology|March 27, 2001
In situ cytokine therapy: redistribution of clonally expanded T cellsP thor Straten, P Guldberg, D Schrama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1999
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTLM H Andersen, J E Bonfill, A Neisig, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Cancer Research|August 17, 2001
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patientsM H Andersen, L O Pedersen, B Capeller, et al.
The British Journal of Dermatology|January 1, 2019
Health literacy: a new piece of the puzzle in psoriasis care? A cross-sectional studyM H Larsen, Y A S Strumse, C R Borge, et al.
Cancer Research|February 24, 2001
Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patientsD Schrama, M H Andersen, P Terheyden, et al.
Scandinavian Journal of Immunology|November 25, 2003
Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progressionP Terheyden, D Schrama, L Ø Pedersen, et al.
Journal of Dairy Science|January 30, 2002
Purification of MUC1 from bovine milk-fat globules and characterization of a corresponding full-length cDNA cloneL T Pallesen, M H Andersen, R L Nielsen, et al.
Scandinavian Journal of Immunology|May 22, 2014
Induction of Bcl-xL-specific cytotoxic T lymphocytes in miceH L Larsen, M H Andersen, H H Wandall, et al.
Leukemia|July 2, 2013
Functional characterization of Foxp3-specific spontaneous immune responsesS K Larsen, S Munir, A Woetmann, et al.
Leukemia|April 11, 2008
Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a 'good' mHag?T Kollgaard, S Reker Hadrup, S L Petersen, et al.
European Journal of Immunology|March 27, 2001
In situ cytokine therapy: redistribution of clonally expanded T cellsP thor Straten, P Guldberg, D Schrama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1999
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTLM H Andersen, J E Bonfill, A Neisig, et al.
Pageof 6